Patients with TP53-mutated MDS fared better than AML patients (for AML patients, a phase 1 study evaluating a combination of AZA + VEN + eprenetapopt in TP53-mutated AML is ongoing (clinicaltrials.gov NCT: NCT04214860)). This evidence concerns the gene TP53 and myelodysplastic syndrome.